
Weilun Lo
Supervisory Patent Examiner (ID: 18192, Phone: (571)272-4847 , Office: P/2179 )
| Most Active Art Unit | 3402 |
| Art Unit(s) | 3747, 3723, 3402, 3748, 2899, 3761, 2179 |
| Total Applications | 2327 |
| Issued Applications | 2049 |
| Pending Applications | 47 |
| Abandoned Applications | 231 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18844516
[patent_doc_number] => 20230406920
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => ANTI-SIGLEC-8 ANTIBODY FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/032788
[patent_app_country] => US
[patent_app_date] => 2021-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032788
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/032788 | ANTI-SIGLEC-8 ANTIBODY FORMULATIONS | Oct 20, 2021 | Pending |
Array
(
[id] => 17385636
[patent_doc_number] => 20220033488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => CANCER TREATMENT BY BLOCKING HOST-INDUCED IL-1 IN COMBINATION WITH RADIOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/451332
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 190
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17451332
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/451332 | Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy | Oct 18, 2021 | Issued |
Array
(
[id] => 18809015
[patent_doc_number] => 20230383350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/249756
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15103
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249756
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/249756 | METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS | Oct 18, 2021 | Pending |
Array
(
[id] => 17520523
[patent_doc_number] => 20220106372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => METHODS, COMPOSITIONS AND USES THEREOF FOR REVERSING SACROPENIA
[patent_app_type] => utility
[patent_app_number] => 17/504158
[patent_app_country] => US
[patent_app_date] => 2021-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504158
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/504158 | Methods, compositions and uses thereof for reversing sarcopenia | Oct 17, 2021 | Issued |
Array
(
[id] => 19121037
[patent_doc_number] => 11965007
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-23
[patent_title] => IL-15-based fusions to IL-7 and IL-21
[patent_app_type] => utility
[patent_app_number] => 17/504100
[patent_app_country] => US
[patent_app_date] => 2021-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 54
[patent_figures_cnt] => 87
[patent_no_of_words] => 34731
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/504100 | IL-15-based fusions to IL-7 and IL-21 | Oct 17, 2021 | Issued |
Array
(
[id] => 18861891
[patent_doc_number] => 20230416326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => MODIFIED INTERLEUKIN-2 (IL-2) MOLECULE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/029673
[patent_app_country] => US
[patent_app_date] => 2021-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029673
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/029673 | MODIFIED INTERLEUKIN-2 (IL-2) MOLECULE AND USE THEREOF | Oct 15, 2021 | Pending |
Array
(
[id] => 19709289
[patent_doc_number] => 20250019431
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => KIDNEY TARGETED IMMUNOTOLERANCE
[patent_app_type] => utility
[patent_app_number] => 18/248398
[patent_app_country] => US
[patent_app_date] => 2021-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248398
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/248398 | KIDNEY TARGETED IMMUNOTOLERANCE | Oct 14, 2021 | Pending |
Array
(
[id] => 18830887
[patent_doc_number] => 20230399412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/248771
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248771
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/248771 | ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF | Oct 11, 2021 | Pending |
Array
(
[id] => 17482211
[patent_doc_number] => 20220089715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/494199
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 119226
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494199 | METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY | Oct 4, 2021 | Pending |
Array
(
[id] => 17385620
[patent_doc_number] => 20220033472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/492440
[patent_app_country] => US
[patent_app_date] => 2021-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17492440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/492440 | Anti-VEGF protein compositions and methods for producing the same | Sep 30, 2021 | Issued |
Array
(
[id] => 20453057
[patent_doc_number] => 12516107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Potent neutralizing antibodies for prevention and treatment of COVID-19
[patent_app_type] => utility
[patent_app_number] => 18/028687
[patent_app_country] => US
[patent_app_date] => 2021-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 15
[patent_no_of_words] => 8936
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028687
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/028687 | Potent neutralizing antibodies for prevention and treatment of COVID-19 | Sep 28, 2021 | Issued |
Array
(
[id] => 18171777
[patent_doc_number] => 11571470
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-07
[patent_title] => IL-15-based fusions to IL-12 and IL-18
[patent_app_type] => utility
[patent_app_number] => 17/486683
[patent_app_country] => US
[patent_app_date] => 2021-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 32
[patent_no_of_words] => 29958
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486683
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/486683 | IL-15-based fusions to IL-12 and IL-18 | Sep 26, 2021 | Issued |
Array
(
[id] => 20178346
[patent_doc_number] => 20250262304
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-21
[patent_title] => FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/246656
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 101913
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246656
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246656 | FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME | Sep 23, 2021 | Pending |
Array
(
[id] => 18971914
[patent_doc_number] => 20240052006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/246512
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37752
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/246512 | ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE | Sep 23, 2021 | Pending |
Array
(
[id] => 18672878
[patent_doc_number] => 20230310324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => METHOD OF MAKING LYOPHILIZED PROTEIN FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/024893
[patent_app_country] => US
[patent_app_date] => 2021-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15555
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024893
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024893 | METHOD OF MAKING LYOPHILIZED PROTEIN FORMULATIONS | Sep 13, 2021 | Pending |
Array
(
[id] => 17704640
[patent_doc_number] => 20220204646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion Polypeptides
[patent_app_type] => utility
[patent_app_number] => 17/471466
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19522
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471466
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/471466 | Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides | Sep 9, 2021 | Issued |
Array
(
[id] => 19226714
[patent_doc_number] => 12006347
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-11
[patent_title] => Superagonists and antagonists of interleukin-2
[patent_app_type] => utility
[patent_app_number] => 17/470246
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 15718
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470246 | Superagonists and antagonists of interleukin-2 | Sep 8, 2021 | Issued |
Array
(
[id] => 20240978
[patent_doc_number] => 12421286
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Il-2 mutant and application thereof
[patent_app_type] => utility
[patent_app_number] => 18/024151
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 61
[patent_no_of_words] => 12375
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024151
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024151 | Il-2 mutant and application thereof | Sep 2, 2021 | Issued |
Array
(
[id] => 17299485
[patent_doc_number] => 20210395324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS
[patent_app_type] => utility
[patent_app_number] => 17/465145
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465145
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/465145 | Multi-level specific targeting of cancer cells | Sep 1, 2021 | Issued |
Array
(
[id] => 18596032
[patent_doc_number] => 20230270823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => LONG-ACTING IL-15 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/023702
[patent_app_country] => US
[patent_app_date] => 2021-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22703
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023702
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/023702 | LONG-ACTING IL-15 AND USES THEREOF | Aug 31, 2021 | Pending |